The effectiveness of Sovodak in patients with novel Corona Virus. ICD-10 code of ‘U07.1 COVID-19, virus identified’ is assigned to a disease diagnosis of COVID-19 confirmed by laboratory testing.
Conditions
Interventions
Intervention 1: Intervention group: sovodak+ribavirin. Intervention 2: Control group: standard care regimen.
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: patients with signing Informed Consent Form Willing Age 18-65 years old Laboratory (RT-PCR) confirmed infection with 2019-nCoV or Lung involvement confirmed with chest CT scan Hospitalized patients with Fever (Oral temperature = 37.8 ?) and at least one of Respiratory rate94% =8 days since illness onset
Exclusion criteria
Exclusion criteria: Known allergic reaction to Sofosbuvir or Daclatasvir Pregnant or breastfeeding women Taking Amiodarone Evidence of multiorgan failure Requiring mechanical ventilation at screening eGFR< 50 mL/min Taking enzyme inducer like Rifampin Receipt of any experimental treatment for COVID-19 prior to the time of the screening Patient with Hb<9
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Need of invasive and non invasive mechanical ventilation ,need of oxygen supplement , the median time for recovery and well-being. Timepoint: daily in all duration of study. Method of measurement: By designed investigator checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamideh Abbaspour Kasgari
Mazandaran University of Medical Sciences
Outcome results
None listed